---
title: "Phio Pharmaceuticals Corp. (PHIO.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/PHIO.US/overview.md"
symbol: "PHIO.US"
name: "Phio Pharmaceuticals Corp."
parent: "https://longbridge.com/zh-HK/quote/PHIO.US.md"
datetime: "2026-04-17T00:47:47.594Z"
locales:
  - [en](https://longbridge.com/en/quote/PHIO.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PHIO.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PHIO.US/overview.md)
---

# Phio Pharmaceuticals Corp. (PHIO.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | 生物技術 |
| 交易所 | US Market |
| 地址 | 411 Swedeland Road, Suite 23-1080, King Of Prussia, Pennsylvania, United States |
| 官網 | [iopharma.com](https://iopharma.com) |

## 公司簡介

Phio Pharmaceuticals Corp.是一家臨床階段的生物制藥公司，專注于在美國開發免疫腫瘤治療藥物。它開發了 PH-762，這是一種 INTASYL 化合物，旨在減少 PD-1 的表達，目前正在進行多中心的 1b 期劑量遞增臨床試驗；PH-894 是一種 INTASYL 化合物，旨在特異性沉默 BRD4，這是一種在 T 細胞和腫瘤細胞中控制基因表達的蛋白，在臨床前研究中進行開發。該公司曾名為 RXi Pharmaceuticals Corporation，並于 2018 年 11 月更名為 Phio Pharmaceuticals Corp

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Robert J. Bitterman | President, CEO & Chairman |
| Lisa C. Carson | CFO, Principal Accounting Officer and VP of Finance & Administration |
| Linda M. Mahoney | Senior Vice President of Development |
| Jennifer Phillips | Senior Vice President of Regulatory & Corporate Affairs |
| Curtis A. Lockshin | Independent Director |
| Jonathan E. Freeman | Independent Director |
| Patricia A. Bradford | Independent Director |
| David H. Deming | Lead Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| Orca Capital GmbH | 4.64% | 2025-12-08 |
| Geode Capital Management, LLC | 0.80% | 2025-12-31 |
| The Vanguard Group, Inc. | 0.75% | 2025-12-31 |
| Macquarie Investment Management Business Trust | 0.43% | 2025-12-31 |
| Cetera Investment Advisers LLC | 0.37% | 2025-12-31 |
| Robert J. Bitterman | 0.36% | 2026-02-05 |
| Northern Trust Global Investments | 0.20% | 2025-12-31 |
| DRW Holdings, LLC | 0.19% | 2025-12-31 |
| Susquehanna International Group, LLP | 0.17% | 2025-12-31 |
| Robert L. Ferrara | 0.13% | 2025-09-11 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| 生物技術 (初創公司) | 21000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Phio Pharmaceuticals Corp. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "生物技術 (初創公司)",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| 美國 | 21000 | 100% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**